Skip to main content
Beijing Scitop Bio-tech Co., Ltd. logo

Beijing Scitop Bio-tech Co., Ltd. — Investor Relations & Filings

Ticker · 300858 ISIN · CNE100004181 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 844 across all filing types
Latest filing 2026-05-20 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300858

About Beijing Scitop Bio-tech Co., Ltd.

https://www.scitop.cn

Beijing Scitop Bio-tech Co., Ltd. focuses on the research, development, and commercialization of probiotics and fermented milk starters. The company operates an extensive strain library, specializing in the isolation and characterization of lactic acid bacteria. Its primary offerings include probiotic powders, functional food ingredients, and customized fermentation solutions tailored for the food, beverage, and healthcare sectors. Scitop integrates advanced fermentation and stabilization technologies to maintain strain viability and efficacy, supported by clinical research and scientific validation. The company provides technical expertise for dairy processing and health supplement formulation, serving diverse applications in human nutrition and animal husbandry.

Recent filings

Filing Released Lang Actions
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is an announcement of the resolutions and voting results from the 2025 Annual General Meeting of shareholders, listing attendance, votes for each proposal, and final outcomes. This clearly matches the ‘Declaration of Voting Results & Voting Rights Announcements’ category.
2026-05-20 Chinese
上海至合律师事务所关于北京科拓恒通生物技术股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 88% confidence The document is a legal opinion letter issued by a law firm certifying the legality of convening and holding the company’s 2025 annual shareholders’ meeting. It is not the meeting materials themselves (e.g., presentations), not the AGM minutes with vote results, nor a proxy statement or formal financial report. Rather, it is a compliance document submitted to the stock exchange. Therefore, it falls under “Regulatory Filings (RNS)” as a miscellaneous statutory/legal disclosure.
2026-05-20 Chinese
第四届董事会第一次会议决议公告
Board/Management Information Classification · 98% confidence The document is a resolution announcement from the company’s fourth board meeting, detailing the election of the board chairman, the formation of board committees, and the appointment of senior management (general manager, deputy managers, CFO, board secretary, etc.). This is clearly a Board/Management Information announcement.
2026-05-20 Chinese
关于董事会完成换届并选举董事长、董事会各专门委员会委员及聘任高级管理人员、内部审计部负责人、证券事务代表的公告
Board/Management Information Classification · 94% confidence The document is an official announcement by Beijing Ketuohengtong Biotechnology Co., Ltd. regarding the completion of the board re-election at the 2025 annual general meeting, election of the board chairman and committee members, and the appointment of senior management personnel, the head of internal audit, and the securities affairs representative. It details changes to the board of directors and senior management. This fits the definition of a Board/Management Information filing.
2026-05-20 Chinese
第一创业证券承销保荐有限责任公司关于北京科拓恒通生物技术股份有限公司2022年向特定对象发行股票并在创业板上市之保荐总结报告书
Regulatory Filings Classification · 85% confidence The document is a “保荐总结报告书” (sponsorship summary report) prepared by the underwriting sponsor after the company’s 2022 targeted share issuance and listing on the ChiNext board. It describes the sponsor’s duties, due diligence, ongoing supervision (“持续督导”) and major events, but contains no financial statements or earnings data. It is a regulatory compliance summary rather than an annual/interim report, earnings release, or direct capital-markets announcement like a prospectus. No specialized category (e.g., 10-K, IR, ER, SHA) precisely fits this post-listing sponsorship report, so it defaults to the general “Regulatory Filings” category.
2026-05-11 Chinese
第一创业证券承销保荐有限责任公司关于北京科拓恒通生物技术股份有限公司2025年度持续督导跟踪报告
Regulatory Filings Classification · 85% confidence The document is a Chinese continuous supervision follow-up report (“持续督导跟踪报告”) prepared by the IPO sponsor for a listed company, detailing compliance reviews, on‐site inspections, sponsor work and remedial measures. It is not an earnings release, annual or interim financial report, proxy statement, or other investor presentation. It is a regulatory compliance filing that does not fit a more specific category and is submitted to exchange regulators as a sponsor’s ongoing compliance report. Therefore it should be classified as a generic Regulatory Filings (RNS).
2026-05-11 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.